PERK: a novel therapeutic target for neurodegenerative diseases?
Tóm tắt
Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative diseases. The promise and caveats of applying this strategy for disease therapy also are discussed.
Tài liệu tham khảo
Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, Ortori CA, Willis AE, Fischer PM, Barrett DA, Mallucci GR: Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med. 2013, 5: 206ra138-
Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T, Atkins C, Liu Q, Rabindran S, Kumar R, Hong X, Goetz A, Stanley T, Taylor JD, Sigethy SD, Tomberlin GH, Hassell AM, Kahler KM, Shewchuk LM, Gampe RT: Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012, 55: 7193-7207. 10.1021/jm300713s.
Wek RC, Cavener DR: Translational control and the unfolded protein response. Antioxid Redox Signal. 2007, 9: 2357-2371. 10.1089/ars.2007.1764.
Trinh MA, Klann E: Translational control by eIF2α kinases in long-lasting synaptic plasticity and long-term memory. Neurobiol Learn Mem. 2013, 105: 93-99.
Wek RC, Jiang H-Y, Anthony TG: Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006, 34: 7-11. 10.1042/BST0340007.
Paschen W, Proud CG, Mies G: Shut-down of translation, a global neuronal stress response: mechanisms and pathological relevance. Curr Pharm Des. 2007, 13: 1887-1902. 10.2174/138161207780858401.
Klann E, Richter JD: Translational control of synaptic plasticity and learning and memory. Translational Control in Biology and Medicine. Edited by: Mathews MB, Sonenberg N, Hershey JW. 2007, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 485-506.
Alberini C: The role of protein synthesis during the labile phases of memory: revisiting the skepticism. Neurobiol Learn Mem. 2008, 89: 234-246. 10.1016/j.nlm.2007.08.007.
Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ: Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 2013, 12: 105-118. 10.1016/S1474-4422(12)70238-7.
Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, Cavener DR, Klann E: Suppression of eIF2α kinases alleviates Alzheimer’s disease-related plasticity and memory deficits. Nat Neurosci. 2013, 16: 1299-1305. 10.1038/nn.3486.
Trinh MA, Kaphzan H, Wek RC, Pierre P, Cavener DR, Klann E: Brain-specific disruption of the eIF2α kinase PERK decreases ATF4 expression and impairs behavioral flexibility. Cell Rep. 2012, 1: 676-688. 10.1016/j.celrep.2012.04.010.
Zhang P, McGrath B, Li S, Frank A, Zambito F, Reinert J, Gannon M, Ma K, McNaughton K, Cavener DR: The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol Cell Biol. 2002, 22: 3864-3874. 10.1128/MCB.22.11.3864-3874.2002.
Senée V, Vattem KM, Delépine M, Rainbow LA, Haton C, Lecoq A, Shaw NJ, Robert JJ, Rooman R, Diatloff-Zito C, Michaud JL, Bin-Abbas B, Taha D, Zabel B, Franceschini P, Topaloglu AK, Lathrop GM, Barrett TG, Nicolino M, Wek RC, Julier C: Wolcott-Rallison syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes. 2004, 53: 1876-1883. 10.2337/diabetes.53.7.1876.
Galasko D, Golde TE: Biomarkers for Alzheimer’s disease in plasma, serum and blood - conceptual and practical problems. Alzheimers Res Ther. 2013, 5: 10-10.1186/alzrt164.
Golde TE: Open questions for Alzheimer’s disease immunotherapy. Alzheimers Res Ther. 2014, 6: 3-10.1186/alzrt233.